Literature DB >> 19520917

Phosphatidylinositol-3-kinase/akt regulates bleomycin-induced fibroblast proliferation and collagen production.

Yongju Lu1, Neelam Azad, Liying Wang, Anand K V Iyer, Vincent Castranova, Bing-Hua Jiang, Yon Rojanasakul.   

Abstract

Abnormal repair and dysregulated angiogenesis have been implicated in the pathogenesis of pulmonary fibrosis, but the underlying mechanisms of regulation are not well understood. The present study investigated the role of phosphatidylinositol-3-kinase (PI3K)/Akt in fibrogenesis of human lung fibroblasts and its regulation by reactive oxygen species (ROS). Exposure of lung fibroblasts to bleomycin, a known inducer of fibrosis, resulted in rapid activation of PI3K/Akt and a parallel increase in fibroblast proliferation and collagen production, characteristics of lung fibrosis. Bleomycin had no significant effect on total Akt protein expression but induced phosphorylation of the protein at threonine 308 and serine 473 positions. Inhibition of this phosphorylation by PI3K inhibitors or by dominant-negative Akt (T308A/S473A) expression abrogated the effects of bleomycin on fibroblast proliferation and collagen production, suggesting the role of PI3K/Akt in the fibrogenic process. Activation of PI3K/Akt by bleomycin also led to transcriptional activation and protein expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor, which contributed to the fibroproliferative and collagen-inducing effects of bleomycin. The fibrogenic effects of bleomycin were dependent on ROS generation, particularly superoxide anion and hydrogen peroxide, which were induced by bleomycin. Inhibition of ROS generation by antioxidant enzymes, catalase and superoxide dismutase mimetic MnTBAP, abrogated the fibrogenic effects of bleomycin as well as its induction of PI3K/Akt and HIF-1alpha activation. Together, our results indicate a novel role of PI3K/Akt in fibrogenesis of human lung fibroblasts and its regulation by ROS, which could be exploited for the treatment of pulmonary fibrosis and related disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19520917      PMCID: PMC2848736          DOI: 10.1165/rcmb.2009-0002OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  53 in total

Review 1.  Matrix metalloproteinases: a tail of a frog that became a prince.

Authors:  Constance E Brinckerhoff; Lynn M Matrisian
Journal:  Nat Rev Mol Cell Biol       Date:  2002-03       Impact factor: 94.444

Review 2.  Mechanisms of pulmonary fibrosis.

Authors:  Victor J Thannickal; Galen B Toews; Eric S White; Joseph P Lynch; Fernando J Martinez
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

Review 3.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

Authors:  Ji Luo; Brendan D Manning; Lewis C Cantley
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

4.  Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension.

Authors:  B H Jiang; G L Semenza; C Bauer; H H Marti
Journal:  Am J Physiol       Date:  1996-10

5.  VEGF production by primary human renal proximal tubular cells: requirement of HIF-1, PI3-kinase and MAPKK-1 signaling.

Authors:  Thomas Hellwig-Bürgel; Daniel P Stiehl; Dörthe M Katschinski; Jan Marxsen; Burkhard Kreft; Wolfgang Jelkmann
Journal:  Cell Physiol Biochem       Date:  2005

6.  Levels of reactive oxygen species and primary antioxidant enzymes in WI38 versus transformed WI38 cells following bleomcyin treatment.

Authors:  Hsiu-Chuan Yen; Hui-Ming Chang; Hideyuki J Majima; Fan-Yi Chen; Sin-Hua Li
Journal:  Free Radic Biol Med       Date:  2005-04-01       Impact factor: 7.376

7.  The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis.

Authors:  Koichi Hamada; Takehiko Sasaki; Pandelakis A Koni; Miyuki Natsui; Hiroyuki Kishimoto; Junko Sasaki; Nobuyuki Yajima; Yasuo Horie; Go Hasegawa; Makoto Naito; Jun-Ichi Miyazaki; Toshio Suda; Hiroshi Itoh; Kazuwa Nakao; Tak Wah Mak; Toru Nakano; Akira Suzuki
Journal:  Genes Dev       Date:  2005-08-17       Impact factor: 11.361

8.  Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells.

Authors:  Ning Gao; Liqin Shen; Zhuo Zhang; Stephen S Leonard; Hengjun He; Xue-Guang Zhang; Xianglin Shi; Bing-Hua Jiang
Journal:  Mol Cell Biochem       Date:  2004-01       Impact factor: 3.396

9.  Emerging information management technologies and the future of disease management.

Authors:  Jeremy J Nobel; Gordon K Norman
Journal:  Dis Manag       Date:  2003

10.  Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species.

Authors:  Ning Gao; Min Ding; Jenny Z Zheng; Zhuo Zhang; Stephen S Leonard; Ke Jian Liu; Xianglin Shi; Bing-Hua Jiang
Journal:  J Biol Chem       Date:  2002-06-17       Impact factor: 5.157

View more
  51 in total

1.  Hypoxic culture and insulin yield improvements to fibrin-based engineered tissue.

Authors:  Jason W Bjork; Lee A Meier; Sandra L Johnson; Zeeshan H Syedain; Robert T Tranquillo
Journal:  Tissue Eng Part A       Date:  2011-12-05       Impact factor: 3.845

2.  Reactive oxygen species-mediated p38 MAPK regulates carbon nanotube-induced fibrogenic and angiogenic responses.

Authors:  Neelam Azad; Anand Krishnan V Iyer; Liying Wang; Yuxin Liu; Yongju Lu; Yon Rojanasakul
Journal:  Nanotoxicology       Date:  2012-01-20       Impact factor: 5.913

3.  A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosis.

Authors:  Yogesh M Kulkarni; Sucharita Dutta; Anand Krishnan V Iyer; Rajkumar Venkatadri; Vivek Kaushik; Vani Ramesh; Clayton A Wright; Oliver John Semmes; Juan S Yakisich; Neelam Azad
Journal:  Proteomics       Date:  2015-11-24       Impact factor: 3.984

4.  Berberine inhibits Smad and non-Smad signaling cascades and enhances autophagy against pulmonary fibrosis.

Authors:  Palanivel Chitra; Gowrikumar Saiprasad; Ramar Manikandan; Ganapasam Sudhandiran
Journal:  J Mol Med (Berl)       Date:  2015-04-17       Impact factor: 4.599

5.  Nickle(II) ions exacerbate bleomycin-induced pulmonary inflammation and fibrosis by activating the ROS/Akt signaling pathway.

Authors:  Lawei Yang; Ziying Lin; Yahong Wang; Chunyan Li; Wenya Xu; Qinglan Li; Weimin Yao; Zeqing Song; Gang Liu
Journal:  Environ Sci Pollut Res Int       Date:  2017-11-28       Impact factor: 4.223

Review 6.  New therapeutics based on emerging concepts in pulmonary fibrosis.

Authors:  Vishwaraj Sontake; Prathibha R Gajjala; Rajesh K Kasam; Satish K Madala
Journal:  Expert Opin Ther Targets       Date:  2018-11-28       Impact factor: 6.902

7.  Klotho, an antiaging molecule, attenuates oxidant-induced alveolar epithelial cell mtDNA damage and apoptosis.

Authors:  Seok-Jo Kim; Paul Cheresh; Mesut Eren; Renea P Jablonski; Anjana Yeldandi; Karen M Ridge; G R Scott Budinger; Dong-Hyun Kim; Myles Wolf; Douglas E Vaughan; David W Kamp
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-04-20       Impact factor: 5.464

8.  MnTBAP Inhibits Bleomycin-Induced Pulmonary Fibrosis by Regulating VEGF and Wnt Signaling.

Authors:  Rajkumar Venkatadri; Anand Krishnan V Iyer; Vani Ramesh; Clayton Wright; Carlos A Castro; Juan S Yakisich; Neelam Azad
Journal:  J Cell Physiol       Date:  2016-09-26       Impact factor: 6.384

9.  Nitric oxide mediates bleomycin-induced angiogenesis and pulmonary fibrosis via regulation of VEGF.

Authors:  Anand Krishnan V Iyer; Vani Ramesh; Carlos A Castro; Vivek Kaushik; Yogesh M Kulkarni; Clayton A Wright; Rajkumar Venkatadri; Yon Rojanasakul; Neelam Azad
Journal:  J Cell Biochem       Date:  2015-11       Impact factor: 4.429

10.  MiR-200a inversely correlates with Hedgehog and TGF-β canonical/non-canonical trajectories to orchestrate the anti-fibrotic effect of Tadalafil in a bleomycin-induced pulmonary fibrosis model.

Authors:  Suzan M Mansour; Hanan S El-Abhar; Ayman A Soubh
Journal:  Inflammopharmacology       Date:  2020-09-10       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.